API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TAK-935 (soticlestat), an oral CH24H enzyme inhbitor, is being developed by Takeda in two Phase 3 trials for Lennox-Gastaut syndrome and Dravet syndrome.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Details:
Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of TAK-935 (soticlestat), being developed by Takeda in two Phase 3 trials for Lennox-Gastaut syndrome and Dravet syndrome.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ligand Pharmaceuticals
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 18, 2023
Details:
Takeda Pharmaceutical secured global rights from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut syndrome.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $856.0 million Upfront Cash: $196.0 million
Deal Type: Termination March 30, 2021
Details:
Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS study).
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: OV935
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time .
Lead Product(s): Soticlestat
Therapeutic Area: Genetic Disease Product Name: TAK-935
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo in the combined Dravet syndrome and Lennox-Gastaut syndrome study population.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ovid Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
Soticlestat continues to appear to be safe and well-tolerated; the majority of the 11 patients showed a reduction in seizures.
Lead Product(s): Soticlestat
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2020